Latest news
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeatMarketBeat · Sun, 09 Aug 2026 06:21:56 GMTIKT Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares - Performance Review - dars.gov.etdars.gov.et · Fri, 07 Aug 2026 20:36:48 GMTPerceptive Advisors LLC Sells 3,106,568 Shares of Inhibikase Therapeutics, Inc. $IKT - MarketBeatMarketBeat · Sun, 02 Aug 2026 10:49:04 GMTInhibikase Therapeutics, Inc. Revenue Breakdown – NASDAQ:IKT - TradingViewTradingView · Sat, 01 Aug 2026 02:14:09 GMT18,030,000-share swap for warrant by Inhibikase Therapeutics, Inc. (IKT) - Stock TitanStock Titan · Fri, 31 Jul 2026 20:33:04 GMTRA Capital group (NASDAQ: IKT) discloses 9.99% capped stake via stock and warrants - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMTH.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - MoomooMoomoo · Fri, 31 Jul 2026 07:00:00 GMTIKT Q1 2026 Earnings: Narrower-than-Expected Loss per Share; Shares Slide 4.3% - Guidance Update - dars.gov.etdars.gov.et · Wed, 29 Jul 2026 21:30:28 GMT